coadministered cagrilintide and semaglutide in adults with overweight or obesity Cagrilintide–Semaglutide Type 2 Diabetes Cagrilintide & Semaglutide in Overweight
Cagrilintide & Semaglutide in Overweight Adults (REDEFINE 1) NEJM Med Journal Club nejm Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 Hypertension Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity NEJM Ahmad Masri Cagrilintide and semaglutide together drive record weight loss in global trial
Pay in 4 interest-free payments of $5.57 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7



